Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors [0.03%]
评价氨基酸输注对胃肠道和胰腺神经内分泌肿瘤患者177Lu-Dotatate药代动力学相互作用的影响
Alicja Puszkiel,Mathilde Bauriaud-Mallet,Roxane Bourgeois et al.
Alicja Puszkiel et al.
Background and objective: 177Lu-Dotatate is a radio-labeled analog of somatostatin used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. In order to prevent nephrotoxic effe...
Clinical Trial
Clinical pharmacokinetics. 2019 Feb;58(2):213-222. DOI:10.1007/s40262-018-0674-1 2019
Author's Reply to Reith: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen" [0.03%]
作者回复瑞斯：“病态肥胖患者对乙酰氨基酚经CYP2E1介导的氧化作用增强”
Anne van Rongen,Pyry A J Välitalo,Catherijne A J Knibbe
Anne van Rongen
Donald M Black,Darren Bentley,Sunny Chapel et al.
Donald M Black et al.
The cholesterol ester transfer protein (CETP) inhibitor dalcetrapib has been under evaluation for its potential to prevent cardiovascular (CV) events for almost two decades. The current clinical development program, representing new advance...
Matthew W McCarthy,Brad Moriyama,Ruta Petraitiene et al.
Matthew W McCarthy et al.
In March 2015, the extended-spectrum triazole antifungal isavuconazole was granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. Isavuconaozle...
Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II [0.03%]
用于健康人群或高胆固醇受试者的阿利库玛的群体药动/药效学分析：使用间接响应模型预测低密度脂蛋白降低：支持生物制品许可申请提交：第二部分
Xavier Nicolas,Nassim Djebli,Clémence Rauch et al.
Xavier Nicolas et al.
Background: Alirocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly lowers low-density lipoprotein cholesterol levels. ...
Clinical Trial
Clinical pharmacokinetics. 2019 Jan;58(1):115-130. DOI:10.1007/s40262-018-0670-5 2019
Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I [0.03%]
基于米氏方程靶标介导的药代动力学模型的阿利库姆ab在健康志愿者或高胆固醇受试者中的群体药代动力学分析：生物制品许可申请资料支持（一）
Jean-Marie Martinez,Aurélie Brunet,Fabrice Hurbin et al.
Jean-Marie Martinez et al.
Background: Alirocumab, a human monoclonal antibody, inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) to significantly reduce low-density lipoprotein cholesterol levels; pharmacokinetics (PK) are governed by...
Clinical Trial
Clinical pharmacokinetics. 2019 Jan;58(1):101-113. DOI:10.1007/s40262-018-0669-y 2019
Jaydeep Sinha,Hesham S Al-Sallami,Stephen B Duffull
Jaydeep Sinha
Background: Allometric scaling is often used to describe the covariate model linking total body weight (WT) to clearance (CL); however, there is no consensus on how to select its value. ...
Correction to: Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials [0.03%]
关于年龄相关因素对拉莫三嗪药代动力学影响的纠正及对未来临床试验维持剂量优化的潜在影响纠正意见
Sven C van Dijkman,Nico C B de Jager,Willem M Rauwé et al.
Sven C van Dijkman et al.
Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Dose Optimisation in Epilepsy Patients should read.
Published Erratum
Clinical pharmacokinetics. 2018 Aug;57(8):1055-1056. DOI:10.1007/s40262-018-0660-7 2018
Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics [0.03%]
从利鲁唑到依达拉奉二十年的求索——仅有的两款肌萎缩侧索硬化症治疗药物的临床药代动力学回顾
Ranjeet Prasad Dash,R Jayachandra Babu,Nuggehally R Srinivas
Ranjeet Prasad Dash
The recent approval of edaravone has provided an intravenous option to treat amyotrophic lateral sclerosis (ALS) in addition to the existing oral agent, riluzole. The present work was primarily undertaken to provide a comprehensive clinical...